- Conditions
- Glaucoma
- Interventions
- Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
- Drug · Procedure · Other
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Dothan, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 22, 2026, 1:44 AM EDT